[1]王喜梅 吴永健.可溶性鸟苷酸环化酶激动剂的心血管保护作用研究进展[J].心血管病学进展,2021,(5):404-407.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.005]
　WANG Ximei,WU Yongjian.Cardiovascular Protective Effect of Soluble Guanylate Cyclase Agonists[J].Advances in Cardiovascular Diseases,2021,(5):404-407.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.005]
点击复制

可溶性鸟苷酸环化酶激动剂的心血管保护作用研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年5期
页码:
404-407
栏目:
综述
出版日期:
2021-05-25

文章信息/Info

Title:
Cardiovascular Protective Effect of Soluble Guanylate Cyclase Agonists
作者:
王喜梅 吴永健
(中国医学科学院 北京 协和医学院 国家 心血管病中心 阜外医院,北京 100037)
Author(s):
WANG Ximei; WU Yongjian
(Fuwai Hospital,National Center of Cardiovascular Diseases,CAMS PUMC,Beijing 100037 ,China)
关键词:
可溶性鸟苷酸环化酶; 可溶性鸟苷酸环化酶激动剂; 心血管疾病
Keywords:
Soluble guanylate cyclase; Soluble guanylate cyclase agonists; Cardiovascular diseases
DOI:
10.16806/j.cnki.issn.1004-3934.2021.05.005
摘要:
近年来，随着一氧化氮-可溶性鸟苷酸环化酶-环鸟苷酸信号通路相关机制研究的不断深入，可溶性鸟苷酸环化酶激动剂在心血管系统的临床应用得到广泛开展。可溶性鸟苷酸环化酶激动剂通过活化下游的环鸟苷酸在抗心肌缺血和抗心力衰竭，改善左心室重塑，降低肺动脉压力，抑制炎症和纤维化，改善心肌代谢等方面发挥重大作用。现就可溶性鸟苷酸环化酶激动剂在心血管系统中的研究进展做一综述。
Abstract:
With the deepening of studies on mechanisms of nitric oxide-soluble guanylate cyclase(sGC)-cGMP signaling pathway,the clinical application of sGC agonists in cardiovascular system has been widely developed in recent years. sGC agonists play an important role in anti myocardial ischemia,anti heart failure,improving left ventricular remodeling, reducing pulmonary artery pressure, inhibiting inflammation and fibrosis,and improv ing myocardial metabolism by activating the downstream cGMP.This article will review the research progress of sGC agonists in cardiovascular system.

参考文献/References:

[1] Stasch JP,Becker EM,Alonso-Alija C,et al. NO-independent regulatory site on soluble guanylate cyclase[J]. Nature,2001,410(6825):212-215.

[2] Boerrigter G,Costello-Boerrigter LC,Cataliotti A,et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure[J]. Circulation,2003,107(5):686-689.

[3] Lapp H,Mitrovic V,Franz N,et al. Cinaciguat(BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure[J]. Circulation,2009,119(21):2781-2788.

[4] Gheorghiade M,Greene SJ,Filippatos G,et al. Cinaciguat,a soluble guanylate cyclase activator:results from the randomized,controlled,phase IIb COMPOSE programme in acute heart failure syndromes[J]. Eur J Heart Fail,2012,14(9):1056-1066.

[5] Erdmann E,Semigran MJ,Nieminen MS,et al. Cinaciguat,a soluble guanylate cyclase activator,unloads the heart but also causes hypotension in acute decompensated heart failure[J]. Eur Heart J,2013,34(1):57-67.

[6] Bonderman D,Pretsch I,Steringer-Mascherbauer R,et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure(DILATE-1):a randomized,double-blind,placebo-controlled,single-dose study[J]. Chest,2014,146(5):1274-1285.

[7] Gheorghiade M,Greene SJ,Butler J,et al. Effect of Vericiguat,a Soluble Guanylate Cyclase Stimulator,on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction:The SOCRATES-REDUCED Randomized Trial[J]. JAMA,2015,314(21):2251-2262.

[8] Pieske B,Maggioni AP,Lam C,et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction:results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study[J]. Eur Heart J,2017,38(15):1119-1127.

[9] Armstrong PW,Pieske B,Anstrom KJ,et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction[J]. N Engl J Med,2020,382(20):1883-1893.

[10] Armstrong PW,Lam C,Anstrom KJ,et al. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction:The VITALITY-HFpEF Randomized Clinical Trial[J]. JAMA,2020,324(15):1512-1521.

[11] Mascherbauer J,Grunig E,Halank M,et al. Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction:study protocol for a randomized controlled trial[J]. Wien Klin Wochenschr,2016,128(23-24):882-889.

[12] Udelson JE,Lewis GD,Shah SJ,et al. Rationale and design for a multicenter,randomized,double-blind,placebo-controlled,phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction(CAPACITY HFpEF)[J]. Am Heart J,2020,222:183-190.

[13] Salloum FN,Das A,Samidurai A,et al. Cinaciguat,a novel activator of soluble guanylate cyclase,protects against ischemia/reperfusion injury:role of hydrogen sulfide[J]. Am J Physiol Heart Circ Physiol,2012,302(6):H1347-H1354.

[14] Methner C,Buonincontri G,Hu CH,et al. Riociguat reduces infarct size and post-infarct heart failure in mouse hearts:insights from MRI/PET imaging[J]. PLoS One,2013,8(12):e83910.

[15] Radovits T,Korkmaz S,Miesel-Groschel C,et al. Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass[J]. Eur J Cardiothorac Surg,2011,39(2):248-255.

[16] Loganathan S,Korkmaz-Icoz S,Radovits T,et al. Effects of soluble guanylate cyclase activation on heart transplantation in a rat model[J]. J Heart Lung Transplant,2015,34(10):1346-1353.

[17] Frankenreiter S,Bednarczyk P,Kniess A,et al. cGMP-Elevating Compounds and Ischemic Conditioning Provide Cardioprotection Against Ischemia and Reperfusion Injury via Cardiomyocyte-Specific BK Channels[J]. Circulation,2017,136(24):2337-2355.

[18] Bonderman D,Ghio S,Felix SB,et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction:a phaseⅡb double-blind,randomized,placebo-controlled,dose-ranging hemodynamic study[J]. Circulation,2013,128(5):502-511.

[19] Zheng X,Zheng W,Xiong B,et al. The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure:a systematic review and meta-analysis[J]. Medicine(Baltimore),2018,97(41):e12709.

[20] Nemeth BT,Matyas C,Olah A,et al. Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload[J]. Sci Rep,2016,6:37166.

[21] Ruppert M,Korkmaz-Icoz S,Li S,et al. Comparison of the Reverse-Remodeling Effect of Pharmacological Soluble Guanylate Cyclase Activation With Pressure Unloading in Pathological Myocardial Left Ventricular Hypertrophy[J]. Front Physiol,2018,9:1869.

[22] Matyas C,Nemeth BT,Olah A,et al. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus[J]. Cardiovasc Diabetol,2015,14:145.

[23] Sawabe T,Chiba T,Kobayashi A,et al. A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation[J]. Pharmacol Res Perspect,2019,7(2):e463.

[24] Naesheim T,How OJ,Myrmel T. The effect of Riociguat on cardiovascular function and efficiency in healthy,juvenile pigs[J]. Physiol Rep,2020,8(17):e14562.

[25] Duca F,Aschauer S,Zotter-Tufaro C,et al. EXPRESS:Riociguat for the treatment of transthyretin cardiac amyloidosis - Data from a named patient use program in Austria[J]. Pulm Circ,2019:766698318.

[26] Ghofrani HA,D’Armini AM,Grimminger F,et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension[J]. N Engl J Med,2013,369(4):319-329.

[27] Makowski CT,Rissmiller RW,Bullington WM. Riociguat:a novel new drug for treatment of pulmonary hypertension[J]. Pharmacotherapy,2015,35(5):502-519.

[28] Lian TY,Jiang X,Jing ZC. Riociguat:a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension[J]. Drug Des Devel Ther,2017,11:1195-1207.

[29] Kramer F,Voss S,Roessig L,et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction[J]. Eur J Heart Fail,2020,22(9):1675-1683.

[30] Ahluwalia A,Foster P,Scotland RS,et al. Antiinflammatory activity of soluble guanylate cyclase:cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment[J]. Proc Natl Acad Sci U S A,2004,101(5):1386-1391.

[31] Shea CM,Price GM,Liu G,et al. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation,fibrosis,and end-organ damage in the Dahl model of cardiorenal failure[J]. Am J Physiol Renal Physiol,2020,318(1):F148-F159.

[32] Kolijn D,Kovacs A,Herwig M,et al. Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator[J]. Front Physiol,2020,11:345.

[33] Witte J,Muhlbauer M,Braun D,et al. Renal soluble guanylate cyclase is downregulated in sunitinib-induced hypertension[J]. J Am Heart Assoc,2018,7(18):e9557.

[34] Friebe A,Sandner P,Schmidtko A. cGMP:a unique 2nd messenger molecule—recent developments in cGMP research and development[J]. Naunyn Schmiedebergs Arch Pharmacol,2020,393(2):287-302.

相似文献/References:

[1]高源 郑刚 李嫣红 张鼎.维利西呱治疗心力衰竭新进展[J].心血管病学进展,2021,(8):698.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.007]
　Gao Yuan Zheng Gang Li Yan Hong Zhang Ding.Treatment of Heart Failure with Vericiguat[J].Advances in Cardiovascular Diseases,2021,(5):698.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.007]
[2]贾晓艳 安晋阳 彭可玲 刘永铭.可溶性鸟苷酸环化酶激动剂治疗射血分数保留性心力衰竭的研究进展[J].心血管病学进展,2022,(2):141.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.012]
　JIA Xiaoyan,AN Jinyang,PENG Keling,et al.Soluble Guanylate Cyclase Stimulators in the Treatment of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(5):141.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.012]
[3]石曈 黄淑田.维利西呱及其抗心力衰竭的研究进展[J].心血管病学进展,2023,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.003]
　SHI Tong,HUANG Shutian.Vericiguat and Its Anti-Heart Failure[J].Advances in Cardiovascular Diseases,2023,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.003]
[4]田师鹏,王立立,陈淑霞,等.维利西呱在心力衰竭方面的研究进展[J].心血管病学进展,2023,(7):602.[doi:10.16806/j.cnki.issn.1004-3934.202.07.007]
　TIAN Shipeng,AN Hui,CHEN Shuxia,et al.Clinical Research Progress of Vericiguat in Heart Failure?/html>[J].Advances in Cardiovascular Diseases,2023,(5):602.[doi:10.16806/j.cnki.issn.1004-3934.202.07.007]

更新日期/Last Update: 2021-06-16